Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by Brinkleyon Feb 18, 2005 10:50am

99 Views

Post# 8615523

RE: Where is the interest???

I read your post 3 times SS. What? They don't fumble the ball south of the boarder. Does that mean you think Adherex will do a good job? They have nothing to carry into the huddle. Does that mean 3 responses on phase 1 trials is no good? Are you on any medication. There are some good ones approved that could substantially improve your lucitity.

Bullboard Posts

Visionstate set to leverage success in the U.S. market